ReviewFrontiers in immunology2026
GlycoRNA in cancer immune regulation and progression: biological mechanisms and translational therapeutic prospects.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence of glycosylated RNA (GlycoRNA) has expanded the paradigm of macromolecular glycosylation beyond proteins and lipids, revealing previously unrecognized layers of regulation within glycoscience and RNA biology. Increasing evidence suggests that GlycoRNA contributes to immune recognition and tumor progression. However, its biological functions and translational potential remain insufficiently characterized. GlycoRNAs are predominantly derived from small non-coding RNAs and are decorated with sialylated and fucosylated N- or O-linked glycans. Processed through canonical glycosylation pathways, they are displayed on the cell surface and contribute to tumor-immune interactions. Sialylated GlycoRNAs can bind sialic acid-binding immunoglobulin-like lectins on immune cells, generating inhibitory signaling that facilitates immune escape. Conversely, partial removal of glycans exposes modified uridine structures such as acp³U, which can activate Toll-like receptor-mediated innate immunity, indicating a glycan-dependent dual regulatory mechanism. Beyond immune regulation, alterations in GlycoRNA abundance are also associated with cancer cell migration, invasion, and metabolic adaptation. In metabolically stressful microenvironments, such as brain metastases, enhanced glycolysis increases substrates, including UDP-GlcNAc, which may further drive GlycoRNA modification and cell-surface presentation, establishing a positive feedback loop linking metabolic reprogramming to immune regulation. Given their stability on tumor cells and in circulation, GlycoRNAs represent promising biomarkers for liquid biopsy and emerging targets for immunotherapy. A comprehensive understanding of GlycoRNA glycosylation, structural determinants, and immune interactions will be essential to guide the development of diagnostic and therapeutic strategies in cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.